• Dr. Ashwin Ananthakrishnan


    My research focuses on understanding the epidemiology of inflammatory bowel diseases, identifying predictors of natural history of disease, and defining high-risk subgroups. The overarching goal of my research is to work towards improving our understanding of the pathogenesis of these diseases, and developing a personalized medicine approach to the management of IBD.

  • Dr. Andrew T. Chan

    Our research is focused on traditional, molecular, and genetic epidemiology of digestive diseases, including colorectal cancer, inflammatory bowel disease, and gastrointestinal bleeding.

  • Dr. Michael Choi

    Dr. Choi

    We study transcriptional regulation of gastrointestinal and hepatobiliary development and its application to regenerative medicine and cancer.

  • Dr. Raymond T. Chung

    Dr. Chung

    Research on hepatitis C persistence and pathogenesis, HCV pathogenesis and HCV and HIV co-infection.

  • Dr. Kathleen Corey

    Our research focuses on understanding the pathogenesis of non-alcoholic fatty liver disease.

  • Dr. Jules Dienstag

    Viral hepatitis (trials of antiviral therapies for chronic hepatitis B and C); antiviral therapy for patients refractory to treatment for chronic hepatitis C; the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial.

  • Dr. Richard Hodin

    Molecular mechanisms of intestinal epithelial growth and differentiation; cell cycle regulation and colon carcinogenesis; thyroid hormone regulation of gut development

  • Dr. Kate Jeffrey

    We are interested in how “epigenetic” mechanisms such as histone modifying enzymes and non-coding RNA regulate inflammation and antiviral immunity.

  • Dr. Lee Kaplan

    Our research efforts include trials of new drugs to combat obesity, and studies examining the genetic and physical factors affecting appetite and fat metabolism.

  • Dr. Peter Kelsey

    Dr. Kelsey

    A prospective comparison of duodenoscope assisted cholangiopancreatoscopy (DACP) and endoscopic retrograde cholangiopancreatography (ERCP) to ERCP alone.

  • Dr. Braden Kuo

    The laboratory is focused upon clinical and translational research in GI motility and visceral pain syndromes such as GERD, gastroparesis, constipation and irritable bowel syndrome.

  • Dr. Georg Lauer

    Understanding the human immune response against viruses, with a focus on T cell responses targeting human hepatotropic viruses (hepatitis C virus (HCV), hepatitis B Virus (HBV), HCV/HIV co-infection). Establishing the groundwork for rational design of antiviral vaccines and immunotherapies.

  • Dr. Emiko Mizoguchi

    Dr Mizoguchi

    Our laboratory interests include intestinal epithelial cell homeostasis under normal and inflammatory conditions and role of epithelial cells in innate immune response.

  • Dr. Alan Mullen

    Understanding how long noncoding RNAs regulate embryonic stem cell differentiation and liver fibrosis

  • Dr. Aylwin Ng

    We are interested in pursuing a systems-level understanding of microbial sensing mechanisms and regulatory control in immune signaling circuits through transcriptional, metabolic and epigenetic programming.

  • Dr. Norman Nishioka

    Dr. Nishioka

    Clinical trial to optimize aminolevulinic acid-based photodynamic therapy of Barrett's esophagus.

  • Dr. Daniel S. Pratt

    Dr. Pratt

    Database and registry for primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and cholangiocarcinoma

  • Dr. Hans-Christian Reinecker

    Dr. Reinecker

    We are interested in the genetic basis and molecular mechanisms of microbial recognition and immune regulation in the digestive tract.

  • Dr. James Richter

    Gastroenterology quality management; colon cancer and polyps; gastrointestinal bleeding; inflammatory bowel disease; gastroesophageal reflux disease

  • Dr. Ramnik Xavier

    Dr Xavier

    Genetic analysis of signal transduction pathways that determine host cell responses to microbes and cancer